We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and ... Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Show more
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today...
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now...
Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administrationReimbursement through Medicare/Medicaid...
WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Based on anticipated net...
Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with...
Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development...
PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.27 | 12.5581395349 | 2.15 | 2.54 | 2.06 | 618794 | 2.29262175 | CS |
| 4 | -0.9 | -27.1084337349 | 3.32 | 3.3495 | 2 | 857302 | 2.58752331 | CS |
| 12 | -1.42 | -36.9791666667 | 3.84 | 4.74 | 2 | 749697 | 3.38167019 | CS |
| 26 | 0.91 | 60.2649006623 | 1.51 | 5.195 | 1.37 | 1212850 | 3.63886882 | CS |
| 52 | 1.13 | 87.5968992248 | 1.29 | 5.195 | 0.9802 | 754791 | 3.20193197 | CS |
| 156 | -2.28 | -48.5106382979 | 4.7 | 5.195 | 0.9802 | 562181 | 3.04704551 | CS |
| 260 | -2.28 | -48.5106382979 | 4.7 | 5.195 | 0.9802 | 562181 | 3.04704551 | CS |
Monksdream
21 hours ago
Invest-in-America
1 month ago
tw0122
1 month ago
Invest-in-America
5 months ago
MiamiGent
5 months ago
Invest-in-America
5 months ago
MiamiGent
5 months ago
Monksdream
7 months ago
makinezmoney
1 year ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
